San Diego, California-based DexCom, Inc. (DXCM) is a medical expertise firm targeted on steady glucose monitoring (CGM) techniques that allow real-time monitoring of blood sugar ranges for folks with diabetes. Valued at $24.7 billion by market cap, its wearable units, such because the G6 and next-generation G7, transmit steady information to smartphones, serving to customers and healthcare suppliers handle glucose ranges extra successfully with out frequent fingerstick testing.
The international chief in glucose biosensing is anticipated to submit its fiscal first-quarter earnings for 2026 after the market closes on Thursday, Apr. 30. Forward of the occasion, analysts count on DXCM to report a revenue of $0.47 per share on a diluted foundation, up 46.9% from $0.32 per share within the year-ago quarter. The corporate beat the consensus estimates in three of the final three quarters whereas lacking the forecast on one event.
For the present 12 months, analysts count on DXCM to report EPS of $2.49, up 19.1% from $2.09 in fiscal 2025. Its EPS is predicted to rise 19.7% 12 months over 12 months to $2.98 in fiscal 2027.
DXCM inventory struggled to maintain up with the broader market over the previous 12 months, and has dipped 6.7%, trailing the S&P 500 Index’s ($SPX) 34.9% beneficial properties and the State Road Well being Care Choose Sector SPDR Fund’s (XLV) 9.8% returns over the identical timeframe.
On Mar. 16, DCXM shares popped over 3% on Mar. 16 as easing crude oil costs improved general market sentiment and decreased inflation considerations. The decline in vitality prices helped stabilize broader indices and boosted investor confidence, driving sector-wide beneficial properties in healthcare shares, together with DexCom, amid a extra favorable macroeconomic backdrop.
Analysts’ consensus opinion on DXCM inventory is bullish, with a “Sturdy Purchase” ranking general. Out of 27 analysts overlaying the inventory, 22 advise a “Sturdy Purchase” ranking, one suggests a “Reasonable Purchase,” three give a “Maintain,” and one recommends a “Sturdy Promote.” DXCM’s common analyst worth goal is $86.75, indicating a possible upside of 35.6% from the present ranges.
On the date of publication, Kritika Sarmah didn’t have (both instantly or not directly) positions in any of the securities talked about on this article. All info and information on this article is solely for informational functions. This text was initially revealed on Barchart.com
